Vinod P. Balachandran

Vinod Balachandran is a surgeon-scientist at Memorial Sloan Kettering Cancer Center whose laboratory has made landmark discoveries elucidating the immunological basis of exceptional survival in pancreatic ductal adenocarcinoma (PDAC) — one of the most immune-excluded and immunotherapy-resistant cancers known. His work has reframed understanding of immune surveillance in PDAC and identified actionable targets for cancer vaccine development. PDAC is characterized by a profoundly immunosuppressive tumor microenvironment, dense desmoplastic stroma, and almost universal resistance to immune checkpoint inhibitors — which have transformed outcomes in many other tumor types. Despite this, a small fraction of PDAC patients (estimated at 3–8%) achieve long-term survival of more than five years after surgery, and Balachandran's central scientific question has been: what immunological characteristics distinguish these exceptional survivors? In a landmark 2017 study published in Nature, Balachandran's team analyzed the immune landscapes of long-term PDAC survivors versus short-term survivors. They found that long-term survivors displayed a higher density of CD8+ T cells in their tumors, and that these T cells were reactive against tumor neoantigens — mutant protein epitopes arising from somatic mutations unique to each patient's cancer. Crucially, the neoantigens recognized in long-term survivors were enriched for high-quality, immunogenic peptides predicted to bind MHC class I molecules with high affinity and to resemble pathogen-derived antigens (high "foreignness"), suggesting that immune recognition of high-quality neoantigens is a determinant of natural immunosurveillance in PDAC. This work provided the first direct evidence that T cell-mediated neoantigen immunosurveillance occurs naturally in pancreatic cancer and defines a subset of patients with favorable outcomes — fundamentally different from the prevailing view that PDAC is immunologically "cold" and cannot be recognized by adaptive immunity. Building on these findings, Balachandran's laboratory has pursued individualized neoantigen vaccines for PDAC. His group participated in the development and clinical testing of mRNA-based personalized neoantigen vaccines in resected PDAC, contributing to a seminal 2023 Nature Medicine study demonstrating that mRNA neoantigen vaccines can expand neoantigen-specific T cell responses after surgery and that vaccine responders show delayed recurrence compared to non-responders. This work sparked enormous interest in cancer vaccines for pancreatic cancer and is being expanded in phase II trials.

Vinod Balachandran 是纪念斯隆-凯特琳癌症中心的外科-科学家，其实验室在阐明胰腺癌长期生存者的免疫学基础方面做出了里程碑式的发现。 他2017年发表于《自然》杂志的标志性研究表明，胰腺癌长期生存者肿瘤中CD8+ T细胞密度更高，这些T细胞能识别高质量的肿瘤新抗原——高度外源性的新抗原驱动了天然免疫监视。这一发现首次证明T细胞介导的新抗原免疫监视可在胰腺癌中自然发生，推翻了胰腺癌"免疫冷漠"的固有观念。他的实验室随后参与了mRNA个性化新抗原疫苗在切除后PDAC中的临床研究，开创了胰腺癌疫苗治疗的新纪元。